TD Cowen Maintains Hold Rating on Beta Bionics, Sets $21 Target

TD Cowen maintained its Hold rating on Beta Bionics and a $21 price target, implying 1.8% downside from the Oct. 27 close of $21.39. The note says the company adjusted its full-year revenue expectations, but the revised figures are not provided.